Q9983 HCPCS Level II code: Florbetaben f18, diagnostic, per study dose, up to 8.1 millicuries
Q9983 is the HCPCS code for “Florbetaben f18, diagnostic, per study dose, up to 8.1 millicuries” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
Q9983Florbetaben f18, diagnostic, per study dose, up to 8.1 millicuries
Short description: Florbetaben f18 diagnostic
HCPCS · United States
Notes for Q9983
As CMS prints them, with any note Q9983 takes from the headings above it.
Note
- CMS processing note 0189: IOM 100-3, CH 4, NCD 220.6.20.
Medicare details
The indicators CMS publishes with Q9983 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- Service not separately priced by Part B (e.g., services not covered, bundled, used by Part A only, etc.)
- ASC
- Approved for ambulatory surgical centers
- Type of service
- Diagnostic radiology
- BETOS category
- Standard imaging - nuclear medicine
- Added
- Jul 1, 2016
Where Q9983 sits
- 1Q codesTemporary codes
- 2Active code Q9983Florbetaben f18, diagnostic, per study dose, up to 8.1 millicuries
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code Q9983 mean?
Q9983 is the HCPCS code for “Florbetaben f18, diagnostic, per study dose, up to 8.1 millicuries” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover Q9983?
CMS lists Q9983’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Service not separately priced by Part B (e.g., services not covered, bundled, used by Part A only, etc.)”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside Q9983
All Q codesQ9977Compounded drug, not otherwise classifiedQ9978Netupitant 300 mg and palonosetron 0.5 mgQ9979Injection, alemtuzumab, 1 mgQ9980Hyaluronan or derivative, genvisc 850, for intra-articular injection, 1 mgQ9981Rolapitant, oral, 1 mgQ9982Flutemetamol f18, diagnostic, per study dose, up to 5 millicuriesQ9984Levonorgestrel-releasing intrauterine contraceptive system (kyleena), 19.5 mgQ9985Injection, hydroxyprogesterone caproate, not otherwise specified, 10 mgQ9986Injection, hydroxyprogesterone caproate, (makena), 10 mgQ9987Pathogen(s) test for plateletsQ9988Platelets, pheresis, pathogen-reduced, each unitQ9989Ustekinumab, for intravenous injection, 1 mg